Optiray (Ioversol)

Ioversol, the active ingredient in Optiray, is a non‑ionic low‑osmolality contrast media presented as a 300 mg/ml solution for intravenous use. It enhances the visibility of vascular structures and organs during radiographic examinations in adult and pediatric patients. GNH USA supplies Optiray as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

GNH USA supplies Optiray as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Optiray is a non‑ionic iodinated contrast agent used in imaging procedures that require vascular or organ enhancement.

- Computed tomography (CT) of the head, chest, abdomen and pelvis: improves delineation of anatomical detail and pathology. - Angiography: provides clear visualization of blood vessels for diagnostic and interventional procedures. - Myelography: enhances the spinal canal and nerve root sleeves for better assessment of spinal pathology. - Urography: highlights the urinary collecting system to aid detection of stones, tumors and obstruction. - Cardiac CT: assists  with  coronary artery assessment  and  cardiac chamber evaluation. - Peripheral vascular imaging: supports evaluation  of  peripheral arteries  and  veins.

Adverse reactions to Optiray may range from mild to severe and should be monitored during and after administration.

Common Side Effects: - Warm sensation or flushing: transient feeling of heat on the skin. - Nausea or vomiting: mild gastrointestinal upset. - Metallic taste: brief metallic sensation in the mouth. - Headache: mild to moderate headache. - Injection site discomfort: mild pain or irritation at the IV site.

Serious or Rare Side Effects: - Hypersensitivity reactions: urticaria, bronchospasm, or anaphylaxis. - Renal impairment: acute kidney injury, especially in patients with pre‑existing renal disease. - Cardiovascular events: hypotension, arrhythmias, or cardiac arrest. - Seizures: rare neurologic events. - Pulmonary edema: fluid accumulation in the lungs. - Death: fatal outcomes in extreme cases of severe reaction.

Before using Optiray, clinicians should assess patient history and monitor for potential adverse events.

- Renal function assessment: evaluate baseline creatinine and eGFR before administration. - Allergy history: verify any prior reactions to iodinated contrast media. - Hydration status: ensure adequate patient hydration to reduce renal risk. - Concomitant nephrotoxic drugs: avoid or adjust dosing of drugs that may worsen kidney function. - Thyroid disease: use caution in patients with hyperthyroidism or thyroid nodules. - Store at ambient temperature: keep in original packaging, protect from light and moisture.

Optiray may interact with other medications, altering safety or efficacy.

Major Interactions (Avoid): - Metformin: increased risk of lactic  lactate  accumulation  due to renal impairment. - High‑dose  iodine supplements  or potassium iodide  :  excess  iodine  load  may  potent  contrast  effects  and  thyroid  disruption  .

Moderate Interactions (Monitor Closely): - Diuretics: may exacerbate volume depletion and renal injury. - ACE inhibitors/ARBs: can increase risk of contrast‑induced nephropathy. - Non‑steroidal anti‑inflamatory  NNSA  NSA   NSA  ...  ...  ...  ...  ...  ...  ...  ...  ...  ...  ...  ...  ...  ...  ...  …  …  …  …  …  …  …  …  …  …  …  …  …  …  …  …  …  …  …  …  …  …  …  …  …  …  …  …  …  …  …